PADI4 levels were significantly increased in the blood of patients with breast carcinomas, hepatocellular carcinomas, lung cancer, esophageal carcinomas, gastric cancer, colon cancer, rectal cancer, pancreatic cancer, ovarian carcinomas, renal cell carcinomas, cervical cancer, prostate carcinomas and bladder carcinomas (p < 0.01), but not in those with endometrial carcinomas, uterine myomas and thyroid carcinomas. Here, PADI4 is linked to hepatocellular carcinoma.